Focus: Johnson & Johnson is a diversified pharmaceutical giant with $85.2B in annual revenue, commanding a major share of global drug markets across oncology, immunology, neuroscience, cardiovascular, and infectious disease. With 131,900 employees and a market cap position as a household name, J&J operates at unmatched scale in Big Pharma.
Profile data last refreshed 22h ago · AI intelligence enriched 1w ago
Hot — 3019 jobs added in 30d
Net +602 (3019 new, 2417 removed). Aggressive expansion phase.
Recent layoff filing — 86 affected
Source: state DOL filings via Big Local News
J&J offers unmatched Big Pharma prestige, resources, and product depth, but recent layoffs and looming patent cliffs create uncertainty around long-term role stability—best for candidates seeking high-impact project work with realistic 3–5 year tenure planning.
Flagship anticoagulant generating 48% of company revenue; FXa inhibitor with sustained market dominance in thromboembolism.
Help build intelligence for Johnson & Johnson
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Johnson & Johnson's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Second-largest revenue driver; long-acting antipsychotic facing patent expiration in 2031, creating near-term cliff exposure.
Androgen receptor inhibitor in oncology with extended patent protection through 2041, representing long-term revenue stability.
Endothelin receptor antagonist facing patent expiration in 2029; part of the $3.2B cliff cohort requiring pipeline replacement.
Prostacyclin receptor agonist with extended LOE protection through 2037; complements OPSUMIT in PAH portfolio.
Interleukin-23 antagonist monoclonal antibody with no defined LOE; represents biologics growth in immunology segment.
Extended-release formulation of INVEGA platform; patent protection extends to 2041, offsetting SUSTENNA cliff risk.
SGLT2 inhibitor facing patent expiration in 2029; earliest LOE cliff trigger among top 10 products, signaling near-term revenue pressure.
249 discontinued, 71 duplicate formulations not shown
+22 more products with revenue data
Johnson & Johnson Just Took $7 Billion in Charges and Still Raised Its Outlook. Here's What That Tells Investors. - AOL.com
Johnson & Johnson Just Took $7 Billion in Charges and Still Raised Its Outlook. Here's What That Tells Investors. AOL.com
Big Pharma Races to Develop Prostate Cancer Drugs - 조선일보
Big Pharma Races to Develop Prostate Cancer Drugs 조선일보
Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher - 24/7 Wall St.
Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher 24/7 Wall St.
J&J reports promising results in three cancer studies - NJBIZ
J&J reports promising results in three cancer studies NJBIZ
Johnson & Johnson Prostate Cancer Drug Shrinks Tumors In Early Stage Trial - TIKR.com
Johnson & Johnson Prostate Cancer Drug Shrinks Tumors In Early Stage Trial TIKR.com
JPMorgan maintains a "Neutral" rating on Johnson & Johnson (JNJ.US): Strong data from two new anti-cancer drugs, but valuation premiums limit upside potential. - Moomoo
JPMorgan maintains a "Neutral" rating on Johnson & Johnson (JNJ.US): Strong data from two new anti-cancer drugs, but valuation premiums limit upside potential. Moomoo
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Recent peer-reviewed publications with author affiliations at this company
Whole heart atherosclerosis volume and risk for major adverse cardiovascular events across the clinical likelihood for obstructive CAD; the CONFIRM2 study.
Variable Selection for the Propensity Score Model: Beyond Main Effects and Linear Relations.
+19 more products
Recent layoffs at headquarters suggest org restructuring is underway; roles in affected divisions carry elevated churn risk, though timing and scale (317 total) are modest relative to 131,900 headcount.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo